康寧傑瑞製藥-B(09966.HK)2019年虧損擴大311% 計劃2021年推出KN046
格隆匯3月31日丨康寧傑瑞製藥-B(09966.HK)發佈公告,截至2019年12月31日止年度,公司取得其他收入人民幣3440萬元(2018年度:人民幣80萬元);年內虧損8.33億元,虧損同比擴大311%。
於截至2019年12月31日止年度,集團的研發開支為人民幣1.67億元,同比增加人民幣1.01億元,此乃主要由於正在進行的臨牀試驗數目增加;臨牀研究規模的擴大;公司候選藥物的臨牀試驗進展及研發人員增加令員工成本增加及薪酬主要因獎勵員工購股權而增加所致。
公司高度差異化的內部管線由八種腫瘤候選藥物組成,其中四種處於臨牀階段。迄今為止,公司尚未商業化任何產品。公司計劃於2020年開始在中國建立我們自身的商業化團隊,將重心初步放在晚期候選藥物及建立一支致力於醫療事宜及政府事宜的團隊,為即將於2021年推出的KN046作準備。
於推出KN046後,公司計劃進一步擴大公司的團隊以積極尋求來自第三方付款人及政府報銷項目的保險及補償機會,從而支持KN046的持續商業運作及即將推出的KN026。公司預計公司的團隊將覆蓋中國的主要省市,尤其是經濟相對發達及可支配收入水平高的省市。公司打算繼續擴大公司的團隊以期望推出更多的產品及獲批更多的適應症。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.